INT102855

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1998
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 9
Disease Relevance 0.91
Pain Relevance 4.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Srgn) extracellular region (Srgn) Golgi apparatus (Srgn)
Anatomy Link Frequency
cerebral cortex 2
striatum 2
cerebellum 1
hippocampus 1
Srgn (Mus musculus)
Pain Link Frequency Relevance Heat
fluoxetine 3 99.84 Very High Very High Very High
Hippocampus 18 99.62 Very High Very High Very High
cerebral cortex 24 99.30 Very High Very High Very High
antidepressant 23 96.70 Very High Very High Very High
Morphine 24 96.20 Very High Very High Very High
Neuronal nitric oxide synthase 1 92.72 High High
narcan 6 90.48 High High
addiction 6 87.36 High High
Dopamine 2 80.04 Quite High
Serotonin 2 79.56 Quite High
Disease Link Frequency Relevance Heat
Anxiety Disorder 8 93.52 High High
Morphine Dependence 6 87.36 High High
INFLAMMATION 1 32.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[direct inhibitor of both nitric oxide synthase (NOS) and soluble guanylate cyclase (sGC)] potentiated the effect of berberine (2 mg/kg, i.p.) in the forced-swim test.
Negative_regulation (inhibitor) of sGC
1) Confidence 0.57 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17585901 Disease Relevance 0 Pain Relevance 0.52
It was found that: (1) cGMP contents in cerebellum, striatum, hippocampus and cerebral cortex were significantly lower. (2) The sGC activities were apparently decreased in cerebellum and striatum.
Negative_regulation (decreased) of sGC in hippocampus associated with hippocampus and cerebral cortex
2) Confidence 0.52 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.09 Pain Relevance 0.52
The decrease of cGMP contents in cerebellum and hippocampus may be due to the decrease of sGC activities, but the decrease of cGMP contents in striatum and cerebral cortex may be mainly due to the increase of PDE activity.
Negative_regulation (decrease) of sGC in cerebral cortex associated with hippocampus and cerebral cortex
3) Confidence 0.52 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.06 Pain Relevance 0.68
Furthermore, a sub-effective dose of (PhSe)(2) (0.1 mg/kg, p.o.) produced a synergistic antidepressant-like effect with N(G)-nitro-L-arginine [L-NNA; 0.3mg/kg, i.p. inhibitor of NOS], (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one [ODQ; 30 pmol/site i.c.v., a specific inhibitor of soluble guanylate cyclase (sGC)], fluoxetine and imipramine in the TST.
Negative_regulation (inhibitor) of sGC associated with antidepressant and fluoxetine
4) Confidence 0.38 Published 2008 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 17936885 Disease Relevance 0.23 Pain Relevance 0.37
The antiimmobility effect of (PhSe)(2) (5 mg/kg, p.o.) in the TST was prevented by pretreatment of mice with L-arginine [a substrate for nitric oxide synthase (NOS)], methylene blue [an inhibitor of NO synthase and sGC] and sildenafil [a phosphodiesterase 5 inhibitor].
Negative_regulation (inhibitor) of sGC
5) Confidence 0.28 Published 2008 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 17936885 Disease Relevance 0.22 Pain Relevance 0.30
It was found that: (1) cGMP contents in cerebellum, striatum, hippocampus and cerebral cortex were significantly lower. (2) The sGC activities were apparently decreased in cerebellum and striatum.
Negative_regulation (decreased) of sGC in cerebral cortex associated with hippocampus and cerebral cortex
6) Confidence 0.18 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.09 Pain Relevance 0.52
It was found that: (1) cGMP contents in cerebellum, striatum, hippocampus and cerebral cortex were significantly lower. (2) The sGC activities were apparently decreased in cerebellum and striatum.
Negative_regulation (decreased) of sGC in cerebellum associated with hippocampus and cerebral cortex
7) Confidence 0.18 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.09 Pain Relevance 0.52
The decrease of cGMP contents in cerebellum and hippocampus may be due to the decrease of sGC activities, but the decrease of cGMP contents in striatum and cerebral cortex may be mainly due to the increase of PDE activity.
Negative_regulation (decrease) of sGC in striatum associated with hippocampus and cerebral cortex
8) Confidence 0.18 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.06 Pain Relevance 0.68
It was found that: (1) cGMP contents in cerebellum, striatum, hippocampus and cerebral cortex were significantly lower. (2) The sGC activities were apparently decreased in cerebellum and striatum.
Negative_regulation (decreased) of sGC in striatum associated with hippocampus and cerebral cortex
9) Confidence 0.18 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.09 Pain Relevance 0.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox